{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:47Z","timestamp":1786980287038,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Neuropsychiatric manifestations occur in about 25% of patients with primary hyperparathyroidism (PHPT). Symptoms can range from depression, anxiety, fatigue or cognitive dysfunction which are commonly observed to more seldomly revealed states of mania, delirium or psychosis which warrant psychiatric intervention. The underlying pathophysiology is likely multifactorial, potentially explained by elevated parathormone and hypercalcemia, with subsequent direct and indirect effects on monoamine neurotransmission and neuroinflammation via monoamine oxidase, tyrosine hydroxylase, sodium-potassium adenosine triphosphatase transporter and interleukin\u20116.<\/jats:p>\n                  <jats:p>This review aims to\u00a0(1) give an overview of the hypothesized pathophysiologic understanding regarding neuropsychiatric manifestations, (2) to summarize the most common neuropsychiatric symptoms and\u00a0(3) to equip clinicians with recommendations for evidence-based tools to detect neuropsychiatric symptoms effectively.<\/jats:p>\n                  <jats:p>Psychometric questionnaires depicting psychiatric symptom burden across PHPT research are highlighted. Cut-off values for psychiatric screening purposes and hypothesized cut-off values in PHPT research to indicate parathyroidectomy are provided. A\u00a0practical approach on how screening for neuropsychiatric symptoms in PHPT might be implemented in routine clinical practice is outlined.<\/jats:p>\n                  <jats:p>Parathyroidectomy is recognized to alleviate neuropsychiatric symptoms in PHPT, with increasing evidence showing persistent improvements in symptoms of depression, anxiety, fatigue and cognitive dysfunction. Clinical practice guidelines still diverge on whether neuropsychiatric manifestations in PHPT warrant parathyroid surgery. A\u00a0symptom-based treatment approach is recommended alongside evaluating surgical intervention.<\/jats:p>","DOI":"10.1007\/s00508-025-02688-3","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T10:51:54Z","timestamp":1767869514000},"page":"232-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neuropsychiatric manifestations of primary hyperparathyroidism"],"prefix":"10.1007","volume":"138","author":[{"given":"Marco","family":"Mairinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godber Mathis","family":"Godbersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8278-191X","authenticated-orcid":false,"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2688_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1136\/pgmj.65.767.628","volume":"65","author":"SJ McAllion","year":"1989","unstructured":"McAllion\u00a0SJ, Paterson\u00a0CR. Psychiatric morbidity in primary hyperparathyroidism. Postgrad Med\u00a0J. 1989;65:628\u201331. https:\/\/doi.org\/10.1136\/pgmj.65.767.628.","journal-title":"Postgrad Med J"},{"key":"2688_CR2","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/jbmr.4679","volume":"37","author":"G El-Hajj Fuleihan","year":"2022","unstructured":"El-Hajj Fuleihan\u00a0G, Chakhtoura\u00a0M, Cipriani\u00a0C, et\u00a0al. Classical and Nonclassical Manifestations of Primary Hyperparathyroidism. J\u00a0Bone Miner Res. 2022;37:2330\u201350. https:\/\/doi.org\/10.1002\/jbmr.4679.","journal-title":"J Bone Miner Res"},{"key":"2688_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2017.16111226","volume":"174","author":"KA Parks","year":"2017","unstructured":"Parks\u00a0KA, Parks\u00a0CG, Onwuameze\u00a0OE, et\u00a0al. Psychiatric Complications of Primary Hyperparathyroidism and Mild Hypercalcemia. Am J Psychiatry. 2017;174:620\u20132. https:\/\/doi.org\/10.1176\/appi.ajp.2017.16111226.","journal-title":"Am J Psychiatry"},{"key":"2688_CR4","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1192\/bjo.2025.10231","volume":"11","author":"S Singh","year":"2025","unstructured":"Singh\u00a0S, Stokes\u00a0V, El Kaubaisy\u00a0AH, et\u00a0al. Primary Hyperparathyroidism and Psychiatry: Manifestations, Causes and Management. BJPsych open. 2025;11:S70. https:\/\/doi.org\/10.1192\/bjo.2025.10231.","journal-title":"BJPsych open"},{"key":"2688_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1176\/appi.psy.48.3.265","volume":"48","author":"SW Brown","year":"2007","unstructured":"Brown\u00a0SW, Vyas\u00a0BV, Spiegel\u00a0DR. Mania in a\u00a0Case of Hyperparathyroidism. Psychosomatics. 2007;48:265\u20138. https:\/\/doi.org\/10.1176\/appi.psy.48.3.265.","journal-title":"Psychosomatics"},{"key":"2688_CR6","doi-asserted-by":"publisher","first-page":"581765","DOI":"10.3389\/fendo.2020.581765","volume":"11","author":"R Minelli","year":"2020","unstructured":"Minelli\u00a0R, Meoli\u00a0A, Tiri\u00a0A, et\u00a0al. An Atypical Presentation of Primary Hyperparathyroidism in an Adolescent: A\u00a0Case Report of Hypercalcaemia and Neuropsychiatric Symptoms Due to a\u00a0Mediastinal Parathyroid Adenoma. Front Endocrinol (lausanne). 2020;11:581765. https:\/\/doi.org\/10.3389\/fendo.2020.581765.","journal-title":"Front Endocrinol (lausanne)"},{"key":"2688_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/bmj.1.5479.85","volume":"1","author":"TD Hockaday","year":"1966","unstructured":"Hockaday\u00a0TD, Keynes\u00a0WM, McKenzie\u00a0JK. Catatonic stupor in elderly woman with hyperparathyroidism. Br Med\u00a0J. 1966;1:85\u20137. https:\/\/doi.org\/10.1136\/bmj.1.5479.85.","journal-title":"Br Med J"},{"key":"2688_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1532-5415.1988.tb01787.x","volume":"36","author":"HC Sier","year":"1988","unstructured":"Sier\u00a0HC, Hartnell\u00a0J, Morley\u00a0JE, et\u00a0al. Primary hyperparathyroidism and delirium in the elderly. J\u00a0Am Geriatr Soc. 1988;36:157\u201370. https:\/\/doi.org\/10.1111\/j.1532-5415.1988.tb01787.x.","journal-title":"J Am Geriatr Soc"},{"key":"2688_CR9","doi-asserted-by":"publisher","first-page":"18nr02356","DOI":"10.4088\/PCC.18nr02356","volume":"20","author":"E Bojdani","year":"2018","unstructured":"Bojdani\u00a0E, Zhang\u00a0T, Shetty\u00a0S, et\u00a0al. Hypercalcemia and Psychosis: Case Report, Review of the Literature, and Management Considerations. Prim Care Companion CNS Disord. 2018;20:18nr02356. https:\/\/doi.org\/10.4088\/PCC.18nr02356.","journal-title":"Prim Care Companion CNS Disord"},{"key":"2688_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/(sici)1098-108x(199907)26:13.0.co;2-u","volume":"26","author":"Y Ozawa","year":"1999","unstructured":"Ozawa\u00a0Y, Koyano\u00a0H, Akama\u00a0T. Complete recovery from intractable bulimia nervosa by the surgical cure of primary hyperparathyroidism. Int J Eat Disord. 1999;26:107\u201310. https:\/\/doi.org\/10.1002\/(sici)1098-108x(199907)26:13.0.co;2-u.","journal-title":"Int J Eat Disord"},{"key":"2688_CR11","volume-title":"ICD-10, the ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research","author":"World Health Organization","year":"1993","unstructured":"World Health Organization. ICD-10, the ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research. Geneva: World Health Organization; 1993."},{"key":"2688_CR12","doi-asserted-by":"publisher","first-page":"e19078","DOI":"10.7759\/cureus.19078","volume":"13","author":"R Serdenes","year":"2021","unstructured":"Serdenes\u00a0R, Lewis\u00a0M, Chandrasekhara\u00a0S. A\u00a0Clinical Review of the Psychiatric Sequelae of Primary Hyperparathyroidism. Cureus. 2021;13:e19078. https:\/\/doi.org\/10.7759\/cureus.19078.","journal-title":"Cureus"},{"key":"2688_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ki.1989.217","volume":"36","author":"M Smogorzewski","year":"1989","unstructured":"Smogorzewski\u00a0M, Campese\u00a0VM, Massry\u00a0SG. Abnormal norepinephrine uptake and release in brain synaptosomes in chronic renal failure. Kidney Int. 1989;36:458\u201365. https:\/\/doi.org\/10.1038\/ki.1989.217.","journal-title":"Kidney Int"},{"key":"2688_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000186831","volume":"61","author":"A Islam","year":"1992","unstructured":"Islam\u00a0A, Smorgorzewski\u00a0M, Zayed\u00a0MA, et\u00a0al. Effect of chronic renal failure with and without secondary hyperparathyroidism on the activities of synaptosomal tyrosine hydroxylase and monoamine oxidase. Nephron. 1992;61:32\u20136. https:\/\/doi.org\/10.1159\/000186831.","journal-title":"Nephron"},{"key":"2688_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/diseases13020054","volume":"13","author":"A Gheorghe","year":"2025","unstructured":"Gheorghe\u00a0A, Nistor\u00a0C, Ranetti\u00a0A, et\u00a0al. An Analysis of Primary Hyperparathyroidism in Association with Depression or Anxiety. Diseases. 2025;13:54. https:\/\/doi.org\/10.3390\/diseases13020054.","journal-title":"Diseases"},{"key":"2688_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.lfs.2009.06.004","volume":"85","author":"X Cao","year":"2009","unstructured":"Cao\u00a0X, Li\u00a0X, Mousseau\u00a0DD. Calcium alters monoamine oxidase\u2014A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signalling pathways. Life Sci. 2009;85:262\u20138. https:\/\/doi.org\/10.1016\/j.lfs.2009.06.004.","journal-title":"Life Sci"},{"key":"2688_CR17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/jpm13050714","volume":"13","author":"C Dettori","year":"2023","unstructured":"Dettori\u00a0C, Ronca\u00a0F, Scalese\u00a0M, et\u00a0al. Parathyroid Hormone (PTH)-Related Peptides Family: An Intriguing Role in the Central Nervous System. J\u00a0Pers Med. 2023;13:714. https:\/\/doi.org\/10.3390\/jpm13050714.","journal-title":"J Pers Med"},{"key":"2688_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archpsyc.65.5.508","volume":"65","author":"WJG Hoogendijk","year":"2008","unstructured":"Hoogendijk\u00a0WJG, Lips\u00a0P, Dik\u00a0MG, et\u00a0al. Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry. 2008;65:508\u201312. https:\/\/doi.org\/10.1001\/archpsyc.65.5.508.","journal-title":"Arch Gen Psychiatry"},{"key":"2688_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/0169-328X(94)00222-Z","volume":"28","author":"DR Weaver","year":"1995","unstructured":"Weaver\u00a0DR, Deeds\u00a0JD, Lee\u00a0K, et\u00a0al. Localization of parathyroid hormone-related peptide (PTHrP) and PTH\/PTHrP receptor mRNAs in rat brain. Mol Brain Res. 1995;28:296\u2013310. https:\/\/doi.org\/10.1016\/0169-328X(94)00222-Z.","journal-title":"Mol Brain Res"},{"key":"2688_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s007010070072","volume":"142","author":"C Evliyaoglu","year":"2000","unstructured":"Evliyaoglu\u00a0C, Carroll\u00a0R, Folkerth\u00a0R, et\u00a0al. Parathyroid Hormone-Related Protein and its Receptor in Human Glial Tumors. Acta Neurochir. 2000;142:871\u20138. https:\/\/doi.org\/10.1007\/s007010070072.","journal-title":"Acta Neurochir"},{"key":"2688_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0169-328X(95)00253-O","volume":"36","author":"M Eggenberger","year":"1996","unstructured":"Eggenberger\u00a0M, Fl\u00fchmann\u00a0B, Muff\u00a0R, et\u00a0al. Structure of a\u00a0parathyroid hormone\/parathyroid hormone-related peptide receptor of the human cerebellum and functional expression in human neuroblastoma SK-N-MC cells. Mol Brain Res. 1996;36:127\u201336. https:\/\/doi.org\/10.1016\/0169-328X(95)00253-O.","journal-title":"Mol Brain Res"},{"key":"2688_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/0196-9781(93)90174-F","volume":"14","author":"S Harvey","year":"1993","unstructured":"Harvey\u00a0S, Hayer\u00a0S. Parathyroid hormone binding sites in the brain. Peptides. 1993;14:1187\u201391. https:\/\/doi.org\/10.1016\/0196-9781(93)90174-F.","journal-title":"Peptides"},{"key":"2688_CR23","doi-asserted-by":"publisher","first-page":"15455","DOI":"10.1074\/jbc.270.26.15455","volume":"270","author":"TB Usdin","year":"1995","unstructured":"Usdin\u00a0TB, Gruber\u00a0C, Bonner\u00a0TI. Identification and Functional Expression of a\u00a0Receptor Selectively Recognizing Parathyroid Hormone, the PTH2 Receptor (\u2217). J\u00a0Biol Chem. 1995;270:15455\u20138. https:\/\/doi.org\/10.1074\/jbc.270.26.15455.","journal-title":"J Biol Chem"},{"key":"2688_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pneurobio.2009.10.017","volume":"90","author":"A Dobolyi","year":"2010","unstructured":"Dobolyi\u00a0A, Palkovits\u00a0M, Usdin\u00a0TB. The TIP39\u2013PTH2 receptor system: Unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms. Prog Neurobiol. 2010;90:29\u201359. https:\/\/doi.org\/10.1016\/j.pneurobio.2009.10.017.","journal-title":"Prog Neurobiol"},{"key":"2688_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.neuroscience.2009.04.054","volume":"162","author":"AG Bag\u00f3","year":"2009","unstructured":"Bag\u00f3\u00a0AG, Dimitrov\u00a0E, Saunders\u00a0R, et\u00a0al. Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience. 2009;162:128\u201347. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.04.054.","journal-title":"Neuroscience"},{"key":"2688_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0306-4522(00)00282-7","volume":"100","author":"T Wang","year":"2000","unstructured":"Wang\u00a0T, Palkovits\u00a0M, Rusnak\u00a0M, et\u00a0al. Distribution of parathyroid hormone\u20112 receptor-like immunoreactivity and messenger RNA in the rat nervous system. Neuroscience. 2000;100:629\u201349. https:\/\/doi.org\/10.1016\/S0306-4522(00)00282-7.","journal-title":"Neuroscience"},{"key":"2688_CR27","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1210\/endo.140.10.7040","volume":"140","author":"SR Hoare","year":"1999","unstructured":"Hoare\u00a0SR, Bonner\u00a0TI, Usdin\u00a0TB. Comparison of rat and human parathyroid hormone 2 (PTH2) receptor activation: PTH is a\u00a0low potency partial agonist at the rat PTH2 receptor. Endocrinology. 1999;140:4419\u201325. https:\/\/doi.org\/10.1210\/endo.140.10.7040.","journal-title":"Endocrinology"},{"key":"2688_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/SLA.0b013e3181f66720","volume":"253","author":"SA Roman","year":"2011","unstructured":"Roman\u00a0SA, Sosa\u00a0JA, Pietrzak\u00a0RH, et\u00a0al. The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg. 2011;253:131\u20137. https:\/\/doi.org\/10.1097\/SLA.0b013e3181f66720.","journal-title":"Ann Surg"},{"key":"2688_CR29","doi-asserted-by":"publisher","first-page":"e13130","DOI":"10.1111\/jne.13130","volume":"34","author":"D Keller","year":"2022","unstructured":"Keller\u00a0D, Tsuda\u00a0MC, Usdin\u00a0TB, et\u00a0al. Behavioural actions of tuberoinfundibular peptide 39 (parathyroid hormone\u00a02). J\u00a0Neuroendocrinol. 2022;34:e13130. https:\/\/doi.org\/10.1111\/jne.13130.","journal-title":"J Neuroendocrinol"},{"key":"2688_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.physbeh.2017.09.005","volume":"181","author":"B Gell\u00e9n","year":"2017","unstructured":"Gell\u00e9n\u00a0B, Zelena\u00a0D, Usdin\u00a0TB, et\u00a0al. The parathyroid hormone 2 receptor participates in physiological and behavioral alterations of mother mice. Physiol Behav. 2017;181:51\u20138. https:\/\/doi.org\/10.1016\/j.physbeh.2017.09.005.","journal-title":"Physiol Behav"},{"key":"2688_CR31","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.neuron.2023.03.030","volume":"111","author":"L Zhang","year":"2023","unstructured":"Zhang\u00a0L, Liu\u00a0N, Shao\u00a0J, et\u00a0al. Bidirectional control of parathyroid hormone and bone mass by subfornical organ. Neuron. 2023;111:1914\u20131932.e6. https:\/\/doi.org\/10.1016\/j.neuron.2023.03.030.","journal-title":"Neuron"},{"key":"2688_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1507\/endocrj.k06-152","volume":"54","author":"Y Chiba","year":"2007","unstructured":"Chiba\u00a0Y, Satoh\u00a0K, Ueda\u00a0S, et\u00a0al. Marked improvement of psychiatric symptoms after parathyroidectomy in elderly primary hyperparathyroidism. Endocr\u00a0J. 2007;54:379\u201383. https:\/\/doi.org\/10.1507\/endocrj.k06-152.","journal-title":"Endocr J"},{"key":"2688_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/s0006-8993(98)00904-4","volume":"811","author":"S Zalcman","year":"1998","unstructured":"Zalcman\u00a0S, Murray\u00a0L, Dyck\u00a0DG, et\u00a0al. Interleukin\u20112 and -6 induce behavioral-activating effects in mice. Brain Res. 1998;811:111\u201321. https:\/\/doi.org\/10.1016\/s0006-8993(98)00904-4.","journal-title":"Brain Res"},{"key":"2688_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41398-019-0570-y","volume":"9","author":"N Yuan","year":"2019","unstructured":"Yuan\u00a0N, Chen\u00a0Y, Xia\u00a0Y, et\u00a0al. Inflammation-related biomarkers in major psychiatric disorders: a\u00a0cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Transl Psychiatry. 2019;9:233. https:\/\/doi.org\/10.1038\/s41398-019-0570-y.","journal-title":"Transl Psychiatry"},{"key":"2688_CR35","doi-asserted-by":"publisher","first-page":"1563967","DOI":"10.3389\/fimmu.2025.1563967","volume":"16","author":"A Gheorghe-Milea","year":"2025","unstructured":"Gheorghe-Milea\u00a0A, St\u0103noiu-P\u00eenzariu\u00a0O, Georgescu\u00a0CE. Unravelling the link between chronic inflammation and primary hyperparathyroidism: a\u00a0systematic review. Front Immunol. 2025;16:1563967. https:\/\/doi.org\/10.3389\/fimmu.2025.1563967.","journal-title":"Front Immunol"},{"key":"2688_CR36","first-page":"125","volume":"56","author":"G Tonini","year":"2004","unstructured":"Tonini\u00a0G, Tat\u00f2\u00a0L, Rigon\u00a0F, et\u00a0al. Hyperparathyroidism. Minerva Pediatr. 2004;56:125\u201331.","journal-title":"Minerva Pediatr"},{"key":"2688_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5498\/wjp.v6.i4.391","volume":"6","author":"SA Rasmussen","year":"2016","unstructured":"Rasmussen\u00a0SA, Mazurek\u00a0MF, Catatonia\u00a0RPI. Our current understanding of its diagnosis, treatment and pathophysiology. World J Psychiatry. 2016;6:391\u20138. https:\/\/doi.org\/10.5498\/wjp.v6.i4.391.","journal-title":"World J Psychiatry"},{"key":"2688_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0306-4530(91)90017-n","volume":"16","author":"C Joborn","year":"1991","unstructured":"Joborn\u00a0C, Hetta\u00a0J, Niklasson\u00a0F, et\u00a0al. Cerebrospinal fluid calcium, parathyroid hormone, and monoamine and purine metabolites and the blood-brain barrier function in primary hyperparathyroidism. Psychoneuroendocrinology. 1991;16:311\u201322. https:\/\/doi.org\/10.1016\/0306-4530(91)90017-n.","journal-title":"Psychoneuroendocrinology"},{"key":"2688_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/jnp.4.1.3","volume":"4","author":"SL Dubovsky","year":"1992","unstructured":"Dubovsky\u00a0SL, Murphy\u00a0J, Christiano\u00a0J, et\u00a0al. The calcium second messenger system in bipolar disorders: data supporting new research directions. J\u00a0Neuropsychiatry Clin Neurosci. 1992;4:3\u201314. https:\/\/doi.org\/10.1176\/jnp.4.1.3.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2688_CR40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.surg.2020.06.006","volume":"169","author":"JY Liu","year":"2021","unstructured":"Liu\u00a0JY, Peine\u00a0BS, Mlaver\u00a0E, et\u00a0al. Neuropsychologic changes in primary hyperparathyroidism after parathyroidectomy from a\u00a0dual-institution prospective study. Surgery. 2021;169:114\u20139. https:\/\/doi.org\/10.1016\/j.surg.2020.06.006.","journal-title":"Surgery"},{"key":"2688_CR41","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/cen.14045","volume":"91","author":"AE Kearns","year":"2019","unstructured":"Kearns\u00a0AE, Espiritu\u00a0RP, Vickers\u00a0DK, et\u00a0al. Clinical characteristics and depression score response after parathyroidectomy in primary hyperparathyroidism. Clin Endocrinol (oxf). 2019;91:464\u201370. https:\/\/doi.org\/10.1111\/cen.14045.","journal-title":"Clin Endocrinol (oxf)"},{"key":"2688_CR42","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/hed.28003","volume":"47","author":"OS Chitnis","year":"2025","unstructured":"Chitnis\u00a0OS, Wagner\u00a0SK, Caraway\u00a0JJ, et\u00a0al. Beck Depression Inventory-II Response Following Parathyroidectomy for Primary Hyperparathyroidism: A\u00a0Systematic Review and Meta-Analyses. Head Neck. 2025;47:1117\u201324. https:\/\/doi.org\/10.1002\/hed.28003.","journal-title":"Head Neck"},{"key":"2688_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ohn.698","volume":"171","author":"J Caraway","year":"2024","unstructured":"Caraway\u00a0J, Ryan\u00a0M, Yang\u00a0A, et\u00a0al. PHQ\u20119 and GAD\u20117 Score Response After Parathyroidectomy for Primary Hyperparathyroidism: a\u00a0Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2024;171:11\u201322. https:\/\/doi.org\/10.1002\/ohn.698.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2688_CR44","doi-asserted-by":"publisher","first-page":"109461","DOI":"10.1016\/j.surg.2025.109461","volume":"184","author":"JJ Ruiz-Manzanera","year":"2025","unstructured":"Ruiz-Manzanera\u00a0JJ, Febrero\u00a0B, L\u00f3pez-L\u00f3pez\u00a0JA, et\u00a0al. Impact of parathyroidectomy on depression symptoms in patients with primary hyperparathyroidism: A\u00a0systematic review and meta-analysis. Surgery. 2025;184:109461. https:\/\/doi.org\/10.1016\/j.surg.2025.109461.","journal-title":"Surgery"},{"key":"2688_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/wjs.12285","volume":"49","author":"Z Song","year":"2025","unstructured":"Song\u00a0Z, Balachandra\u00a0S, Wu\u00a0C, et\u00a0al. Risk of neuropsychiatric disorders in primary hyperparathyroidism: Parathyroidectomy versus nonoperative management. World J Surg. 2025;49:106\u201314. https:\/\/doi.org\/10.1002\/wjs.12285.","journal-title":"World J Surg"},{"key":"2688_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jss.2021.01.029","volume":"263","author":"KB Montgomery","year":"2021","unstructured":"Montgomery\u00a0KB, Fazendin\u00a0JM, Lindeman\u00a0B, et\u00a0al. Tired of Being Ignored: Fatigue as a\u00a0Presenting Symptom in Primary Hyperparathyroidism. J\u00a0Surg Res. 2021;263:53\u20136. https:\/\/doi.org\/10.1016\/j.jss.2021.01.029.","journal-title":"J Surg Res"},{"key":"2688_CR47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.surg.2013.09.005","volume":"154","author":"SE Murray","year":"2013","unstructured":"Murray\u00a0SE, Pathak\u00a0PR, Pontes\u00a0DS, et\u00a0al. Timing of symptom improvement after parathyroidectomy for primary hyperparathyroidism. Surgery. 2013;154:1463\u20139. https:\/\/doi.org\/10.1016\/j.surg.2013.09.005.","journal-title":"Surgery"},{"key":"2688_CR48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1348\/1359107041557048","volume":"9","author":"J De Vries","year":"2004","unstructured":"De Vries\u00a0J, Michielsen\u00a0H, Van Heck\u00a0GL, et\u00a0al. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol. 2004;9:279\u201391. https:\/\/doi.org\/10.1348\/1359107041557048.","journal-title":"Br J Health Psychol"},{"key":"2688_CR49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00268-013-2273-5","volume":"38","author":"L Rolighed","year":"2014","unstructured":"Rolighed\u00a0L, Amstrup\u00a0AK, Jakobsen\u00a0NFB, et\u00a0al. Muscle function is impaired in patients with \u201casymptomatic\u201d primary hyperparathyroidism. World J Surg. 2014;38:549\u201357. https:\/\/doi.org\/10.1007\/s00268-013-2273-5.","journal-title":"World J Surg"},{"key":"2688_CR50","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/s0002-9343(89)80613-8","volume":"87","author":"SA Turken","year":"1989","unstructured":"Turken\u00a0SA, Cafferty\u00a0M, Silverberg\u00a0SJ, et\u00a0al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med. 1989;87:553\u20137. https:\/\/doi.org\/10.1016\/s0002-9343(89)80613-8.","journal-title":"Am J Med"},{"key":"2688_CR51","doi-asserted-by":"publisher","unstructured":"Bj\u00f6rnsdotter-\u00d6berg S, Koman A, Skorpil M, et\u00a0al. Parathyroidectomy Restores Muscle Strength and Transcriptome in Individuals with Primary Hyperparathyroidism. J\u00a0Clin Endocrinol Metab.2025:dgaf418. https:\/\/doi.org\/10.1210\/clinem\/dgaf418.","DOI":"10.1210\/clinem\/dgaf418"},{"key":"2688_CR52","doi-asserted-by":"publisher","first-page":"7060","DOI":"10.3390\/ijms26157060","volume":"26","author":"V Nguyen","year":"2025","unstructured":"Nguyen\u00a0V, Lee\u00a0K, Moon\u00a0YJ. Parathyroid Hormone as a\u00a0Modulator of Skeletal Muscle: Insights into Bone-Muscle and Nerve-Muscle Interactions. Int J Mol Sci. 2025;26:7060. https:\/\/doi.org\/10.3390\/ijms26157060.","journal-title":"Int J Mol Sci"},{"key":"2688_CR53","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1308\/rcsann.2021.0062","volume":"103","author":"D Cagney","year":"2021","unstructured":"Cagney\u00a0D, Razzaq\u00a0Z, Majeed\u00a0M, et\u00a0al. Primary hyperparathyroidism causing posterior reversible encephalopathy syndrome: a\u00a0case report. Ann R Coll Surg Engl. 2021;103:e341\u2013e4. https:\/\/doi.org\/10.1308\/rcsann.2021.0062.","journal-title":"Ann R Coll Surg Engl"},{"key":"2688_CR54","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s12020-024-04041-6","volume":"86","author":"SS Rallapalli","year":"2024","unstructured":"Rallapalli\u00a0SS, Rayani\u00a0M, Ninan\u00a0GA, et\u00a0al. Posterior reversible encephalopathy syndrome and parkinsonism as the first manifestation of primary hyperparathyroidism\u2014a\u00a0report of two cases. Endocrine. 2024;86:937\u201342. https:\/\/doi.org\/10.1007\/s12020-024-04041-6.","journal-title":"Endocrine"},{"key":"2688_CR55","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.4158\/ACCR-2018-0504","volume":"5","author":"CMG Augusto","year":"2019","unstructured":"Augusto\u00a0CMG, de Morais\u00a0NS, Santana\u00a0RP, et\u00a0al. Parkinsonism As An Atypical Manifestation Of Primary Hyperparathyroidism. Aace Clin Case Rep. 2019;5:e244\u2013e6. https:\/\/doi.org\/10.4158\/ACCR-2018-0504.","journal-title":"Aace Clin Case Rep"},{"key":"2688_CR56","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1210\/jc.2018-01225","volume":"103","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian\u00a0JP. Primary Hyperparathyroidism. J\u00a0Clin Endocrinol Metab. 2018;103:3993\u20134004. https:\/\/doi.org\/10.1210\/jc.2018-01225.","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR57","doi-asserted-by":"publisher","first-page":"e0127574","DOI":"10.1371\/journal.pone.0127574","volume":"10","author":"I Lourida","year":"2015","unstructured":"Lourida\u00a0I, Thompson-Coon\u00a0J, Dickens\u00a0CM, et\u00a0al. Parathyroid hormone, cognitive function and dementia: a\u00a0systematic review. PLoS ONE. 2015;10:e127574. https:\/\/doi.org\/10.1371\/journal.pone.0127574.","journal-title":"PLoS ONE"},{"key":"2688_CR58","doi-asserted-by":"publisher","first-page":"103985","DOI":"10.1016\/j.archger.2019.103985","volume":"87","author":"W Jiang","year":"2020","unstructured":"Jiang\u00a0W, Hu\u00a0C, Li\u00a0F, et\u00a0al. Elevated parathyroid hormone levels and cognitive function: A\u00a0systematic review. Arch Gerontol Geriatr. 2020;87:103985. https:\/\/doi.org\/10.1016\/j.archger.2019.103985.","journal-title":"Arch Gerontol Geriatr"},{"key":"2688_CR59","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1212\/WNL.0000000000004290","volume":"89","author":"SM Kim","year":"2017","unstructured":"Kim\u00a0SM, Zhao\u00a0D, Schneider\u00a0ALC, et\u00a0al. Association of parathyroid hormone with 20-year cognitive decline: The ARIC study. Neurology. 2017;89:918\u201326. https:\/\/doi.org\/10.1212\/WNL.0000000000004290.","journal-title":"Neurology"},{"key":"2688_CR60","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1210\/jc.2014-1736","volume":"99","author":"E Hagstr\u00f6m","year":"2014","unstructured":"Hagstr\u00f6m\u00a0E, Kilander\u00a0L, Nylander\u00a0R, et\u00a0al. Plasma parathyroid hormone is associated with vascular dementia and cerebral hyperintensities in two community-based cohorts. J\u00a0Clin Endocrinol Metab. 2014;99:4181\u20139. https:\/\/doi.org\/10.1210\/jc.2014-1736.","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.surg.2023.07.045","volume":"175","author":"WR Lightle","year":"2024","unstructured":"Lightle\u00a0WR, Zheng\u00a0F, Makris\u00a0KI, et\u00a0al. Objectively measured cognitive dysfunction in patients with primary hyperparathyroidism improves after parathyroidectomy. Surgery. 2024;175:161\u20135. https:\/\/doi.org\/10.1016\/j.surg.2023.07.045.","journal-title":"Surgery"},{"key":"2688_CR62","doi-asserted-by":"publisher","first-page":"zraa029","DOI":"10.1093\/bjsopen\/zraa029","volume":"5","author":"A Koman","year":"2021","unstructured":"Koman\u00a0A, Br\u00e4nstr\u00f6m\u00a0R, Pernow\u00a0Y, et\u00a0al. Prediction of cognitive response to surgery in elderly patients with primary hyperparathyroidism. Bjs Open. 2021;5:zraa29. https:\/\/doi.org\/10.1093\/bjsopen\/zraa029.","journal-title":"Bjs Open"},{"key":"2688_CR63","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke\u00a0K, Spitzer\u00a0RL, Williams\u00a0JB. The PHQ-9: validity of a\u00a0brief depression severity measure. J\u00a0Gen Intern Med. 2001;16:606\u201313. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x.","journal-title":"J Gen Intern Med"},{"key":"2688_CR64","doi-asserted-by":"publisher","DOI":"10.1037\/t00742-000","volume-title":"Beck Depression Inventory-II (BDI-II)","author":"AT Beck","year":"1996","unstructured":"Beck\u00a0AT, Steer\u00a0RA, Brown GK.\u00a0Beck Depression Inventory-II (BDI-II). 1996. https:\/\/doi.org\/10.1037\/t00742-000."},{"key":"2688_CR65","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond\u00a0AS, Snaith\u00a0RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361\u201370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x.","journal-title":"Acta Psychiatr Scand"},{"key":"2688_CR66","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer\u00a0RL, Kroenke\u00a0K, Williams\u00a0JBW, et\u00a0al. A\u00a0brief measure for assessing generalized anxiety disorder: the GAD\u20117. Arch Intern Med. 2006;166:1092\u20137. https:\/\/doi.org\/10.1001\/archinte.166.10.1092.","journal-title":"Arch Intern Med"},{"key":"2688_CR67","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein\u00a0MF, Folstein\u00a0SE, McHugh\u00a0PR. \u201cMini-mental state\u201d. A\u00a0practical method for grading the cognitive state of patients for the clinician. J\u00a0Psychiatr Res. 1975;12:189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"2688_CR68","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine\u00a0ZS, Phillips\u00a0NA, B\u00e9dirian\u00a0V, et\u00a0al. The Montreal Cognitive Assessment, MoCA: a\u00a0brief screening tool for mild cognitive impairment. J\u00a0Am Geriatr Soc. 2005;53:695\u20139. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x.","journal-title":"J Am Geriatr Soc"},{"key":"2688_CR69","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1111\/jgs.18902","volume":"72","author":"S Klil-Drori","year":"2024","unstructured":"Klil-Drori\u00a0S, Bodenstein\u00a0KC, Sun\u00a0S, et\u00a0al. Montreal Cognitive Assessment (MoCA) XpressO: Validation of a\u00a0digital self-administered cognitive prescreening tool. J\u00a0Am Geriatr Soc. 2024;72:2516\u201322. https:\/\/doi.org\/10.1111\/jgs.18902.","journal-title":"J Am Geriatr Soc"},{"key":"2688_CR70","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00423-021-02173-1","volume":"406","author":"T Weber","year":"2021","unstructured":"Weber\u00a0T, Dotzenrath\u00a0C, Dralle\u00a0H, Niederle\u00a0B, et\u00a0al. Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK). Langenbeck\u2019s Arch Surg. 2021;406:571\u201385. https:\/\/doi.org\/10.1007\/s00423-021-02173-1.","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"2688_CR71","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/jbmr.4677","volume":"37","author":"JP Bilezikian","year":"2022","unstructured":"Bilezikian\u00a0JP, Khan\u00a0AA, Silverberg\u00a0SJ, et\u00a0al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J\u00a0Bone Miner Res. 2022;37:2293\u2013314. https:\/\/doi.org\/10.1002\/jbmr.4677.","journal-title":"J Bone Miner Res"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02688-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:03:34Z","timestamp":1776755014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02688-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":71,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2688"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02688-3","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.\u00a0Kasper served as a\u00a0consultant or on advisory boards for Angelini, Biogen, Boehringer, Esai, Janssen, IQVIA, Mylan, Otsuka Inc., Recordati, Rovi and Schwabe and has served on speakers bureaus for Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Recordati, Schwabe, Servier and Sothema. M.\u00a0Mairinger and G.M.\u00a0Godbersen declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}